

Image

1617

CERTIFICATE OF MAILING 37 C.F.R. § 1.8

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date below:

February 5, 2004

Date

Shelley P.M. Fussey

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Philip E. Thorpe and Sophia Ran

Serial No.: 09/351,862

Filed: July 12, 1999

For: CANCER TREATMENT KITS USING

ANTIBODIES TO

AMINOPHOSPHOLIPIDS

Group Art Unit: 1617

Examiner: Sharareh, S.

Atty. Dkt. No.: 4001.002282

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

In compliance with the duty of disclosure under 37 C.F.R. § 1.56, it is respectfully requested that this Supplemental Information Disclosure Statement be entered and the document listed on attached Form PTO-1449 be considered by the Examiner and made of record in the present case. A copy of the listed document required by 37 C.F.R. § 1.98(a)(2) is enclosed for the convenience of the Examiner.

In accordance with 37 C.F.R. §§ 1.97(g),(h), this Supplemental Information Disclosure Statement is not to be construed as a representation that a search has been made, and is not to be construed to be an admission that the information cited is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).

A Request for Continued Examination (RCE) has been filed in the present application.

Accordingly, this Supplemental Information Disclosure Statement is being filed prior to the

mailing of a final Official Action, notice of allowance or an Action that closes prosecution under

37 C.F.R. § 1.97(c). This Supplemental Information Disclosure Statement is therefore timely

filed in accordance with 37 C.F.R. § 1.97(c) without a fee in light of the following information.

In accordance with 37 C.F.R. § 1.97(e)(2), it is hereby certified that the document listed

in the accompanying Form PTO-1449 was not cited in a communication from a foreign patent

office in a counterpart foreign application. The listed document was cited in an Official Action

on the merits in a co-pending application of the present inventors, Serial No. 10/376,194

(Attorney Docket No. 3999.000597), mailed from the P.T.O. on January 13, 2004, less than three

months before the filing of the present statement, and evidently could not have been submitted

before receipt.

Should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason

relating to this Supplemental Information Disclosure Statement, the Examiner should contact the

undersigned representative to discuss deduction from Williams, Morgan & Amerson Deposit

Account No. 50-0786/4001.002282.

Respectfully submitted,

Williams, Morgan & Amerson, P.C.

Customer No. 23720

Shelley P.M. Fussey, Ph.D.

Reg. No. 39,458

Agent for Applicants

10333 Richmond, Suite 1100 Houston, Texas, 77042 (713) 934-4079

Date: February 5, 2004

2

Page 1 Fam PTO-1449 (modified) Atty. Docket No. Serial No. 4001.002282 09/351,862 of Patents and Publications for Applicant's **Applicant** Thorpe and Ran INFORMATION DISCLOSURE STATEMENT Filing Date: Group: (Use several sheets if necessary) July 12, 1999 1617 **Foreign Patent Documents** Other Art **U.S. Patent Documents** See Page See Page See Page 1

•			U.S. Patent De	ocuments			
Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.
			Foreign Patent		1	0	
Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No
	Other	Art (Includ	ing Author, Title	e, Date Pert	inent F	ages,	Etc.)
Exam.	Ref. Des.			Citation			•

C80

Edition, pages 51 and 57-58, 1996.

Hardman et al., In Goodman & Gilman's The Pharmacological Basis of Therapeutics Ninth

EXAMINER:	DATE CONSIDERED: